Drug trade bodies rally patient groups to deflect calls for full trial dataBMJ 2013; 347 doi: https://doi.org/10.1136/bmj.f4702 (Published 23 July 2013) Cite this as: BMJ 2013;347:f4702
- Adrian O’Dowd
Two leading pharmaceutical trade bodies planned to secure the support of patients’ groups to try to resist growing calls for much greater transparency of clinical trial data, it has emerged.
An emailed memo sent to several drug companies from two trade association bodies, which was leaked to the Guardian newspaper on 22 July, showed that there were plans to recruit patient groups to resist moves that would force companies to publish more raw trial data.
The memo came from the European Federation of Pharmaceutical Industries and Associations and Pharmaceutical Research and Manufacturers of America.
Currently, drug companies publish only some results of their clinical trials, but the European Commission is seeking to change regulations in its clinical trials directive, while the European Medicines Agency is running a public consultation on the issue.
Proposed changes would mean that companies would have to publish all clinical trial results in a public database, regardless of whether or not …